As of November 6, 2026, DBV Technologies S.A. is a publicly traded company (Nasdaq: DBVT); its largest reported holder is Adage Capital, with 7.31% on Schedule 13G/A of May 13, 2026, then Raymond Debbane (6.5%) (Schedule 13G/A, May 13, 2026).
Is this your company?
About to sign with, pay or invest in DBV Technologies S.A.? See the free Snapshot first.
Free to see. No signup.
Is DBV Technologies S.A. a real, registered company?
- DBV Technologies S.A. files with the SEC under CIK 1613780 (its SEC filings).
- Its shares are listed under the ticker DBVT on Nasdaq (also DBVTF) (SEC company record).
- Incorporated in I0, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under DBV Technologies S.A. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names MPM BioImpact LLC (filed 2026-08-14).
Who are DBV Technologies S.A.'s owners and officers?
DBV Technologies S.A.: industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-08-14).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2025-04-17)
- : Executive Officer (Form D, 2025-04-17)
- : Executive Officer (Form D, 2025-04-17)
- : Director (Form D, 2025-04-17)
- : Director (Form D, 2025-04-17)
- : Director (Form D, 2025-04-17)
- : Director (Form D, 2025-04-17)
- : Director (Form D, 2025-04-17)
- : Director (Form D, 2025-04-17)
- : Director (Form D, 2025-04-17)
- : Director (Form D, 2025-04-17)
- : Director (Form D, 2025-04-17)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Mpm Bioimpact LLC | 6.2% |
| Schedule 13G, 2026-08-06 | Ra Capital Management, L.P. | 5.8% |
| Schedule 13G/A, 2026-05-15 | Mpm Bioimpact LLC | 8.8% |
| Schedule 13G/A, 2026-05-13 | Artisan Partners Asset Management Inc. | 3.7% |
| Schedule 13G/A, 2026-05-13 | Adage Capital Management, L.P. | 7.31% |
| Schedule 13G/A, 2026-05-12 | Vivo Opportunity Fund Holdings, L.P. | 4% |
| Schedule 13G/A, 2026-05-05 | Raymond Debbane | 6.5% |
| Schedule 13G, 2026-02-17 | Mpm Bioimpact LLC | 9.9% |
| Schedule 13G/A, 2026-02-17 | Kenneth Griffin | 3.5% |
| Schedule 13G/A, 2026-02-17 | Venrock Healthcare Capital Partners Ii, L.P. | 0% |
| Schedule 13G/A, 2026-02-13 | Vivo Opportunity Fund Holdings, L.P. | 5.7% |
| Schedule 13G/A, 2026-02-13 | Raymond Debbane | 6.2% |
Questions about who owns DBV Technologies S.A.
Who owns DBV Technologies S.A.?
On this page, 4 holders' latest ownership filings report 5% or more of DBV Technologies S.A.: Adage Capital Management, L.P. (7.31%, Schedule 13G/A, filed 2026-05-13), Raymond Debbane (6.5%, Schedule 13G/A, filed 2026-05-05), Mpm Bioimpact LLC (6.2%, Schedule 13G/A, filed 2026-08-14) and Ra Capital Management, L.P. (5.8%, Schedule 13G, filed 2026-08-06).
Who are the largest shareholders of DBV Technologies S.A.?
By the share each holder's latest filing reports, the largest holders of DBV Technologies S.A. on this page are Adage Capital Management, L.P. (7.31%), Raymond Debbane (6.5%) and Mpm Bioimpact LLC (6.2%).
When did Adage Capital Management, L.P. buy into DBV Technologies S.A.?
The filings give report dates, not purchase dates. The earliest filing from Adage Capital Management, L.P. on this page is the Schedule 13G/A, filed 2026-05-13, reporting 7.31%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on DBV Technologies S.A.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on DBV Technologies S.A.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on DBV Technologies S.A. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own DBV Technologies S.A. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Caisse Des Depots ET Consignations: 7,529,502 shares (2.4% of shares outstanding), held indirectly through a bpifrance participations s.a., on a joint filing (Form 4, 2025-12-19).
- Bpifrance SA: 7,529,502 shares (2.4% of shares outstanding), held indirectly through a bpifrance participations s.a., on a joint filing (Form 4, 2025-12-19).
- Bpifrance Investissement S.A.S.: 7,529,502 shares (2.4% of shares outstanding), held indirectly through a bpifrance participations s.a., on a joint filing (Form 4, 2025-12-19).
- Bpifrance Epic: 7,529,502 shares (2.4% of shares outstanding), held indirectly through a bpifrance participations s.a., on a joint filing (Form 4, 2025-12-19).
- Bpifrance Participations SA: 7,529,502 shares (2.4% of shares outstanding), held indirectly through a bpifrance participations s.a., on a joint filing (Form 4, 2025-12-19).
Shares outstanding: 314,388,807 as of 2026-10-26, from the company's latest SEC cover page.
How much has DBV Technologies S.A. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-04-17 | $306.90M | $306.90M |
Keep reading
More on DBV Technologies S.A. and the records around it.
DBV Technologies S.A. elsewhere on the record
- 5%+ stake filings Aug 2026
- Form D filing Apr 2025
Companies that share a holder
- Venrock Healthcare Capital Partners II, L.P. also filed stake reports on 1 other company: Cogent Biosciences, Inc. (Aug 2025)
- Bpifrance Participations S.A. also filed stake reports on 4 other companies: Cellectis S.A. (Nov 2026), Pasqal Holding SA (Sep 2026), Constellium SE (May 2026)
- MPM BioImpact LLC also filed stake reports on 4 other companies: Climb Bio, Inc. (Aug 2026), Context Therapeutics Inc. (Aug 2026), Forte Biosciences, Inc. (May 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/dbv-technologies-sa